491 related articles for article (PubMed ID: 17693992)
1. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
6. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
Toda M; Martuza RL; Rabkin SD
Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
[TBL] [Abstract][Full Text] [Related]
10. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
11. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
12. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer.
Day KV; Li D; Liu S; Guo M; O'Malley BW
Laryngoscope; 2001 May; 111(5):801-6. PubMed ID: 11368071
[TBL] [Abstract][Full Text] [Related]
14. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
15. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
17. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov NG; Fraefel C; Breakefield XO
Hum Gene Ther; 2000 Jul; 11(10):1429-38. PubMed ID: 10910140
[TBL] [Abstract][Full Text] [Related]
18. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
19. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
20. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
